Predictors of longer-term outcome in the Vienna omega-3 high-risk study
Schitophrenia Research, DOI: http://dx.doi.org/10.1016/j.schres.2017.08.010
Nilufar Mossahebr, Nilufar Mossaheb, Nilufar Mossaheb, Miriam R. Schäfer, Miriam R. Schäfer, Monika Schlögelhofer Monika Schlögelhofer, Claudia M. Klier, Claudia M. Klier, Stefan . . .
- Omega-3 reduces many psychiatric disorders – 2 reviews 2016
- Schizophrenia treated by 6 months of Omega-3 – RCT Nov 2015
- Omega-3 reduced aggressive incidents in prisoners by 30 percent – RCT June 2018
- Violent schizophrenia patients treated by 3 months of Omega-3 – RCT Aug 2017
- Omega-3 for just 3 months greatly reduced psychosis for 80 months – RCT Aug 2015
different publication, different authors, same data
Overview Schizophrenia and Vitamin D contains the following summary
14 reasons to think that schizophrenia is associated with low vitamin D
1) 97% of patients with schizophrenia are vitamin D deficient
2) Schizophrenia varies with latitude (UVB) by 10X (controversy)
3) Schizophrenia is more common in those with dark skin (when away from the equator)
4) Schizophrenia is associated with low natal vitamin D
5) Schizophrenia has been increasing around the world when vitamin D has been decreasing (controversy)
6) Schizophrenia is associated with low birth rate, which is associated with low vitamin D
7) Schizophrenia is associated with Autism which is associated with low vitamin D
8) Schizophrenia Bulletin Editorial (Jan 2014) speculated that Vitamin D could be a major player
9) Schizophrenia 2X more likely if low vitamin D - meta-analysis
10) Schizophrenia increased 40 % for Spring births after Danes stopped vitamin D fortification
11) Schizophrenia is associated with season of birth
12) Schizophrenia is associated with poor Vitamin D Receptor genes
13) Schizophrenia risk is decreased if give Vitamin D after birth
14) Schizophrenia symptoms reduced when Vitamin D levels are restored
Items in BOTH of the categories Cognition and Omega-3
- Risk of Alzheimer’s is decreased by food, supplements, and lifestyle – Aug 2024
- APOE-04 Alzheimer’s progression slowed up by Omega-3 – RCT Aug 2024
- Dementia prevented by Omega-3, Vitamin D, etc. book and video May 2024
- Better cognition associated with higher Omega-3 index – Sept 2023
- Alzheimer’s delayed 4.7 years by high Omega-3 index (7.6 years if also have APOE-4) June - 2022
- Dementia 4.1 X high risk in those with low Vitamin D, Omega-3, etc.2 decades before (behind paywall) – Nov 2021
- Early brain development helped by Iron, Iodine, Vitamin D, Omega-3. Zinc etc. – Oct 2021
- Omega-3 paused Alzheimer's decline - RCT Sept 2021
- Seafood (Omega-3) during pregnancy increased childhood IQ by 8 points – review Dec 2019
- Omega-3 index of 6 to 7 associated with best cognition in this study – Nov 2019
- Eating fish improves cognition (Omega-3 fish during pregnancy in this case) - Oct 2019
- Mental disorders fought by Omega-3 etc. - meta-meta-analysis Oct 2019
- Omega-3 prevents Parkinson’s Disease – Review of RCT July 2019
- Omega-3 helps brains of seniors – May 2019
- Omega-3 helped Alzheimer’s only if good level of B vitamins – RCT April 2019
- Standard Omega-3 not get past blood-brain barrier in seniors at high risk of Alzheimer’s – Patrick hypothesis Oct 2018
- APOE4 gene problems (Alzheimer’s) reduced by both Vitamin D and Omega-3 - Dec 2018
- Omega-3 is important for Brain Health during all phases of life – Aug 2018
- Hypothesis: Omega-3 reduces Alzheimer’s directly and via the gut – Sept 2018
- Improve Cognitive Health and Memory with Vitamin D and Omega-3 – World Patent March 2018
- IQ levels around the world are falling (perhaps lower Vitamin D, Iodine, or Omega-3)
- Adding Vitamin D, Omega-3, etc to children’s milk improved memory (yet again) – RCT June 2018
- Omega-3, Vitamin D, Folic acid etc. during pregnancy and subsequent mental illness of child – March 2018
- Why Alzheimer’s studies using Omega-3 have mixed results – quality, dose size, Omega-6, genes, etc. March 2018
- Benefits of Omega-3 beyond heart health - LEF Feb 2018
- Supplementation while pregnant and psychotic – 20 percent Omega-3, 6 percent Vitamin D – June 2016
- ADHD, Autism, Early Psychosis and Omega-3 – review Dec 2017
- Mild Traumatic Brain Injury prevented with Omega-3, Resveratrol, etc (in rats) – Oct 2017
- Omega-3 found to treat Alzheimer’s and Parkinson’s in animals – Sept 2017
- The End of Alzheimer's and Dementia if adjust Vitamin D, B-12, Iron, Omega-3, etc.
- Violent schizophrenia patients treated by 3 months of Omega-3 – RCT Aug 2017
- Psychosis risk reduced for 80 weeks by just 12 weeks of Omega-3 – RCT Aug 2017
- Alzheimer’s (apoE4) may require more than Omega-3 - May 2017
- Infants getting 1 g of Omega-3 for 12 weeks got better brains – RCT March 2017
- Omega-3 reduces many psychiatric disorders – 2 reviews 2016
- Cognitive Impairment 1.8 times more likely if low Omega-3– Oct 2016
- Omega-3 may treat schizophrenia
- Benefits of Omega-3 on brain development
- Omega-3 helps childhood cognition – meta-analysis April 2016
- Football Brain injuries prevented by Omega-3 – RCT Jan 2016
- Schizophrenia treated by 6 months of Omega-3 – RCT Nov 2015
- Omega-3 and infant development - dissertation Sept 2015
- Omega-3 etc improved both cognition and mobility of older women – Aug 2015
- Schizophrenia relapses reduced 3X by Omega-3 – RCT Mar 2015
- Cognitive decline in elderly slowed by Omega-3 – meta-analysis May 2015
- Cognitively impaired brain atrophy was slowed 40 percent by Omega-3 and B vitamins – RCT July 2015
- Omega-3, Vitamin D, and other nutrients decrease mental health problems – March 2015
- Vitamin D, Omega-3 supplementation helps cognition – perhaps due to serotonin – Feb 2015
- Vitamin D and Omega-3 may reduce cortical atrophy with age – Nov 2013
- Alzheimer’s and Vitamins D, B, C, E, as well as Omega-3, metals, etc. – June 2013
Longer-term data on ω-3 polyunsaturated fatty acids (PUFA) for prevention of psychosis in (ultra high risk) UHR individuals have initially shown promising results.
This analysis aimed to assess clinical predictors of longer-term outcome in UHR individuals treated with ω-3 PUFAs versus placebo.
Data derived from an RCT in 81 UHR individuals treated with ω-3 PUFAs versus placebo for 12 weeks and follow-up assessment after a median of 6.7 years.
Baseline GAF, baseline PANSS global score, pre-to-post-intervention change in EPA (Eicosapentaenoic acid) level were significant predictors of transition to psychosis, PANSS negative score and baseline MADRS reached trend-levels. In the final multivariate Cox regression analysis change in EPA levels remained the only significant predictor.
Taking into account all other significant predictors, changes in EPA levels were found to be the single most significant predictor for transition to psychosis in a longer term observation of UHR individuals.